Abstract
Objective: To explore the function of p42.3 in gastric carcinoma.
Methods: We summarized the intricate regulation of p42.3 in gastric carcinoma from several aspects, namely, the structure features, the expression level, its regulation on cell cycle and EMT, its relationship with miR-29a as well as the optimal feedback circuit involved in. Results: We addressed the complex functions of p42.3 in regulating EMT, migration, invasion, proliferation and the optimal regulation network in GC, as well as the significant up/down-stream signal molecules involved in the pathway. We have also illuminated that miR-29a can inhibit cell proliferation and block the cell cycle, at least in part, via the repression of p42.3. Conclusion: In short, p42.3 might serve as a potential therapeutic target in the treatment of GC.Keywords: p42.3, gastric carcinoma, cell cycle, EMT, miR-29a, therapeutic target.
Letters in Drug Design & Discovery
Title:p42.3 in Gastric Carcinoma: A Novel Biomarker and Promising Therapeutic Target
Volume: 14 Issue: 10
Author(s): Hui Jing, Lu-Lu Wei, Fu-Chun Huo, Xin Ren, Jun-Nian Zheng*Dong-Sheng Pei*
Affiliation:
- Department of pathology, Xuzhou Medical University, Xuzhou 221000, China, 209 Tongshan Road, Xuzhou, Jiangsu,China
- Department of pathology, Xuzhou Medical University, Xuzhou 221000, China, 209 Tongshan Road, Xuzhou, Jiangsu,China
Keywords: p42.3, gastric carcinoma, cell cycle, EMT, miR-29a, therapeutic target.
Abstract: Objective: To explore the function of p42.3 in gastric carcinoma.
Methods: We summarized the intricate regulation of p42.3 in gastric carcinoma from several aspects, namely, the structure features, the expression level, its regulation on cell cycle and EMT, its relationship with miR-29a as well as the optimal feedback circuit involved in. Results: We addressed the complex functions of p42.3 in regulating EMT, migration, invasion, proliferation and the optimal regulation network in GC, as well as the significant up/down-stream signal molecules involved in the pathway. We have also illuminated that miR-29a can inhibit cell proliferation and block the cell cycle, at least in part, via the repression of p42.3. Conclusion: In short, p42.3 might serve as a potential therapeutic target in the treatment of GC.Export Options
About this article
Cite this article as:
Jing Hui, Wei Lu-Lu , Huo Fu-Chun, Ren Xin , Zheng Jun-Nian *, Pei Dong-Sheng*, p42.3 in Gastric Carcinoma: A Novel Biomarker and Promising Therapeutic Target, Letters in Drug Design & Discovery 2017; 14 (10) . https://dx.doi.org/10.2174/1570180814666170306121357
DOI https://dx.doi.org/10.2174/1570180814666170306121357 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Dysfunction of Mitochondrial ATP Production As a Target for Personalized Cancer Therapy
Current Pharmacogenomics and Personalized Medicine Host Pharmacogenetics in the Treatment of HIV and Cancer
Current Drug Safety From Na+/K+-ATPase and Cardiac Glycosides to Cytotoxicity and Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Circulating MicroRNAs as Potential Biomarkers in Glioma: A Mini-Review
Endocrine, Metabolic & Immune Disorders - Drug Targets The Therapeutic Potential of Adenosine Triphosphate as an Immune Modulator in the Treatment of HIV/AIDS: A Combination Approach with HAART
Current HIV Research Renal Cell Carcinoma Cancer Stem Cells as Therapeutic Targets
Current Signal Transduction Therapy Therapeutic Challenges in Neuroendocrine Tumors
Anti-Cancer Agents in Medicinal Chemistry Physical and Chemical Stimuli-Responsive Drug Delivery Systems: Targeted Delivery and Main Routes of Administration
Current Pharmaceutical Design Colloidal Supramolecular Aggregates for Therapeutic Application in Neuromedicine
Current Medicinal Chemistry Anticancer Drug Combinations, How Far We can Go Through?
Anti-Cancer Agents in Medicinal Chemistry The Human Glioma-Associated Oncogene Homolog 1 (GLI1) Family of Transcription Factors in Gene Regulation and Diseases
Current Genomics Oxidative Stress, Redox Signaling and Cancer Chemoresistance: Putting Together the Pieces of the Puzzle
Current Medicinal Chemistry ABC Transporter Inhibitors in Reversing Multidrug Resistance to Chemotherapy
Current Drug Targets From French Paradox to Cancer Treatment: Anti-cancer Activities and Mechanisms of Resveratrol
Anti-Cancer Agents in Medicinal Chemistry Perspectives in Engineered Mesenchymal Stem/Stromal Cells Based Anti- Cancer Drug Delivery Systems
Recent Patents on Anti-Cancer Drug Discovery Base Excision Repair: Contribution to Tumorigenesis and Target in Anticancer Treatment Paradigms
Current Medicinal Chemistry Syntheses and Preliminary Evaluation of Dual Target PET Probe [<sup>18</sup>F]-NOTA-Gly3- E (2PEG4-RGD-WH701) for PET Imaging of Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Regulation by IFN-α/IFN-γ Co-Formulation (HerberPAG<sup>®</sup>) of Genes Involved in Interferon-STAT-Pathways and Apoptosis in U87MG
Current Topics in Medicinal Chemistry MicroRNA-34b Inhibits Pancreatic Cancer Metastasis Through Repressing Smad3
Current Molecular Medicine Threes Company: Regulation of Cell Fate by Statins
Current Drug Targets - Cardiovascular & Hematological Disorders